Topics

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients

2019-11-12 18:25:30 | BioPortfolio

Summary

A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients

Description

The purpose of this study is to evaluate efficacy and safety of TG-2349 in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I infected patients. Approximately 360 subjects will be enrolled in this study and divided into 2 groups:

Group 1: Chronic hepatics C virus (HCV) genotype 1 infected, non-cirrhotic subjects.

Group 2: Chronic hepatics C virus (HCV) genotype 1 infected, cirrhotic subjects.

Study Design

Conditions

Chronic Hepatics C Virus (HCV) Genotype 1

Intervention

TG-2349, DAG181, Ribavirin

Location

Beijing Tsinghua Changgung Hospital
Beijing
China

Status

Recruiting

Source

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-11-12T18:25:30-0500

Clinical Trials [1566 Associated Clinical Trials listed on BioPortfolio]

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.

To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

To evaluate the drug-drug reactions between TG-2349 and DAG181, and the pharmacokinetics and tolerability profile in healthy Chinese volunteers to be the reference for protocol designs of ...

Phase 2 Study of Yimitasvir Phosphate Capsules

The safety, tolerability and antiviral activity of DAG181/SoF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection

Phase 3 Study of Yimitasvir Phosphate Capsules

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to conventio...

PubMed Articles [10697 Associated PubMed Articles listed on BioPortfolio]

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.

Patients infected with hepatitis C virus (HCV) treated with interferon-free direct-acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit it...

Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation: A report of two cases.

Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have demonstrated that immunocompromised patients such as those receiving solid-organ transplantati...

Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin.

The major dose-limiting toxicity of ribavirin is hemolytic anemia. We investigated the incidence, risk factors and impact on virological response of anemia in chronic hepatitis C genotype 2 patients r...

Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.

Based on previously published results, 12 weeks of sofosbuvir 400mg/day plus ribavirin, the current DAA regimen reimbursed by Bureau-of National-Health-Insurance (BNHI) of Taiwan for genotype-2 CHC is...

Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.

We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representat...

Medical and Biotech [MESH] Definitions

Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.

A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.

An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.

INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.

More From BioPortfolio on "A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...


Searches Linking to this Trial